BioCentury
ARTICLE | Company News

Aubagio gets European approval for MS

August 30, 2013 11:58 PM UTC

The European Commission approved an MAA from Sanofi (Euronext:SAN; NYSE:SNY) for Aubagio teriflunomide to treat relapsing-remitting multiple sclerosis (RRMS). Sanofi said it plans to launch Aubagio in Europe "in the coming months," with the first launch slated for October in Germany. Sanofi's Genzyme Corp. unit already markets the dihydroorotate dehydrogenase (DHODH) inhibitor in the U.S., Australia and Argentina for relapsing forms of MS. ...